[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE167803T1 - Hemmung der replikation des influenza-virus durch oligonukleotide - Google Patents

Hemmung der replikation des influenza-virus durch oligonukleotide

Info

Publication number
ATE167803T1
ATE167803T1 AT91909830T AT91909830T ATE167803T1 AT E167803 T1 ATE167803 T1 AT E167803T1 AT 91909830 T AT91909830 T AT 91909830T AT 91909830 T AT91909830 T AT 91909830T AT E167803 T1 ATE167803 T1 AT E167803T1
Authority
AT
Austria
Prior art keywords
influenza virus
oligonucleotides
inhibition
virus replication
ability
Prior art date
Application number
AT91909830T
Other languages
English (en)
Inventor
Sudhir Agrawal
Josef M E Leiter
Peter Palese
Paul C Zamecnik
Original Assignee
Worcester Found Ex Biology
Sinai School Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Worcester Found Ex Biology, Sinai School Medicine filed Critical Worcester Found Ex Biology
Application granted granted Critical
Publication of ATE167803T1 publication Critical patent/ATE167803T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT91909830T 1990-04-30 1991-04-29 Hemmung der replikation des influenza-virus durch oligonukleotide ATE167803T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/516,275 US5194428A (en) 1986-05-23 1990-04-30 Inhibition of influenza virus replication by oligonucleotide phosphorothioates

Publications (1)

Publication Number Publication Date
ATE167803T1 true ATE167803T1 (de) 1998-07-15

Family

ID=24054870

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91909830T ATE167803T1 (de) 1990-04-30 1991-04-29 Hemmung der replikation des influenza-virus durch oligonukleotide

Country Status (7)

Country Link
US (1) US5194428A (de)
EP (1) EP0527906B1 (de)
JP (1) JPH05506997A (de)
AT (1) ATE167803T1 (de)
CA (1) CA2081777A1 (de)
DE (1) DE69129694D1 (de)
WO (1) WO1991016902A1 (de)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637573A (en) * 1986-05-23 1997-06-10 Agrawal; Sudhir Influenza virus replication inhibiting oligonucleotide analogues and their pharmaceutical compositions
DE3835772A1 (de) * 1988-10-20 1990-04-26 Deutsches Krebsforsch Tumorhemmende saccharid-konjugate
US20040142899A1 (en) * 1990-01-11 2004-07-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US6753423B1 (en) 1990-01-11 2004-06-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US6339066B1 (en) 1990-01-11 2002-01-15 Isis Pharmaceuticals, Inc. Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
US5959096A (en) * 1992-03-16 1999-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
JPH06501843A (ja) * 1990-08-14 1994-03-03 アイシス・ファーマシューティカルス・インコーポレーテッド アンチセンスオリゴヌクレオチドによるインフルエンザａ型ウイルス，アン・アーバｈ２ｎ２株の阻害
US5359052A (en) * 1991-08-05 1994-10-25 Polish Academy Of Sciences Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
US5646267A (en) * 1991-08-05 1997-07-08 Polish Academy Of Sciences Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
US6369209B1 (en) 1999-05-03 2002-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US7119184B2 (en) 1991-08-12 2006-10-10 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en) 1991-11-19 2012-04-10 Isis Pharmaceuticals, Inc. Composition and methods for the pulmonary delivery of nucleic acids
WO1993013114A1 (en) 1991-12-24 1993-07-08 Isis Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR MODULATING β-AMYLOID
US5681747A (en) * 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
US6153599A (en) * 1992-03-16 2000-11-28 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
US6537973B1 (en) 1992-03-16 2003-03-25 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
US5922686A (en) * 1992-03-16 1999-07-13 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of protein kinase C
US5916807A (en) * 1992-03-16 1999-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US5885970A (en) * 1992-03-16 1999-03-23 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US6117847A (en) * 1992-03-16 2000-09-12 Isis Pharmaceuticals, Inc. Oligonucleotides for enhanced modulation of protein kinase C expression
US5882927A (en) * 1992-03-16 1999-03-16 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
US5643780A (en) * 1992-04-03 1997-07-01 Isis Pharmaceuticals, Inc. Compositions and methods for modulating RNA activity through modification of the 5' cap structure of RNA
TW244371B (de) * 1992-07-23 1995-04-01 Tri Clover Inc
US6346614B1 (en) 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
US20040049021A1 (en) * 1992-09-10 2004-03-11 Anderson Kevin P. Compositions and mehtods for treatment of Hepatitis C virus-associated diseases
US6995146B2 (en) 1992-09-10 2006-02-07 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
NZ255578A (en) * 1992-09-10 1996-11-26 Chemo Sero Therapeut Res Inst Antisense oligonucleotides complementary and hybridizable to a portion of hepatitis c virus and their use in treating hepatitis c virus associated diseases
US6391542B1 (en) 1992-09-10 2002-05-21 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus-associated diseases
US6174868B1 (en) 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US6423489B1 (en) 1992-09-10 2002-07-23 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus-associated diseases
US5523389A (en) * 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
US5985558A (en) 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
JPH08507752A (ja) * 1993-01-08 1996-08-20 ハイブライドン インコーポレイテッド 二量体ブロックの合成と二量体ブロックを使ったオリゴヌクレオチド結合法
US6087491A (en) * 1993-01-08 2000-07-11 Hybridon, Inc. Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks
WO1994017091A2 (en) * 1993-01-21 1994-08-04 Hybridon Inc. Foldback triplex-forming oligonucleotides
WO1994017093A1 (en) * 1993-01-25 1994-08-04 Hybridon, Inc. Oligonucleotide alkylphosphonates and alkylphosphonothioates
EP0693123A1 (de) * 1993-03-31 1996-01-24 HYBRIDON, Inc. Veränderte Oligonukleotide mit verbesserter anti-grippe Aktivität
AU679566B2 (en) 1993-09-03 1997-07-03 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
US5837852A (en) * 1993-10-14 1998-11-17 Bristol-Myers Squibb Company Capped nucleic acid oligomers that inhibit cap-dependent transcription of the influenza virus endonuclease
US5807838A (en) * 1994-09-23 1998-09-15 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of multidrug resistance-associated protein
US5510239A (en) * 1993-10-18 1996-04-23 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of multidrug resistance-associated protein
US5550047A (en) * 1994-02-18 1996-08-27 University Of Massachusetts Oligonucleotides with anti-Epstein-Barr virus activity
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5801235A (en) * 1994-05-25 1998-09-01 Hybridon, Inc. Oligonucleotides with anti-cytomegalovirus activity
US20060142236A1 (en) * 1994-05-31 2006-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6090626A (en) * 1994-05-31 2000-07-18 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of raf gene expression
KR100211178B1 (ko) * 1994-05-31 1999-07-15 파샬 비. 린네 라프유전자 발현의 안티센스 올리고뉴클레오티드 조절
US20030119769A1 (en) * 1994-05-31 2003-06-26 Monia Brett P Antisense oligonucleotide modulation of raf gene expression
US5563255A (en) * 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5744362A (en) * 1994-05-31 1998-04-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5656612A (en) * 1994-05-31 1997-08-12 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6410518B1 (en) 1994-05-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
EP0763050B1 (de) * 1994-06-01 2000-01-05 Hybridon, Inc. Verzweigte Oligonukleotide als pathogenhemmende Mittel
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US5475109A (en) * 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
US6117993A (en) * 1995-05-23 2000-09-12 Hybridon, Inc. Synthons for oligonucleotide synthesis
US5750674A (en) * 1995-05-23 1998-05-12 Hybridon, Inc. Methods and compounds for the stereoselective enrichment of oligonucleotide diastereomers and oligonucleotides thereby produced
US5693773A (en) * 1995-06-07 1997-12-02 Hybridon Incorporated Triplex-forming antisense oligonucleotides having abasic linkers targeting nucleic acids comprising mixed sequences of purines and pyrimidines
US5985662A (en) * 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US5652356A (en) * 1995-08-17 1997-07-29 Hybridon, Inc. Inverted chimeric and hybrid oligonucleotides
US6624293B1 (en) 1995-08-17 2003-09-23 Hybridon, Inc. Modified protein kinase A-specific oligonucleotides and methods of their use
US7074768B2 (en) 1995-08-17 2006-07-11 Idera Pharmaceuticals, Inc. Modified protein kinase A-specific oligonucleotides and methods of their use
US5837854A (en) * 1996-04-05 1998-11-17 University Of Massachusetts Oligonucleotides with anti-Epstein-Barr virus activity
US5856099A (en) * 1996-05-21 1999-01-05 Isis Pharmaceuticals, Inc. Antisense compositions and methods for modulating type I interleukin-1 receptor expression
AU6592496A (en) * 1996-07-22 1998-02-10 Hybridon, Inc. Compositions and methods for treating specific gene expression-related diseases and disorders in humans
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5886165A (en) * 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
US5885834A (en) * 1996-09-30 1999-03-23 Epstein; Paul M. Antisense oligodeoxynucleotide against phosphodiesterase
US6001991A (en) * 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
US6319906B1 (en) 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6077833A (en) * 1996-12-31 2000-06-20 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US20040023917A1 (en) * 1996-12-31 2004-02-05 Bennett C. Frank Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7235653B2 (en) * 1996-12-31 2007-06-26 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6265388B1 (en) 1997-03-21 2001-07-24 President And Fellows Of Harvard College Antisense inhibition of angiogenin expression
WO1999001579A1 (en) 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US6809193B2 (en) 1997-08-13 2004-10-26 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US5877309A (en) * 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US20070149472A1 (en) * 1997-08-13 2007-06-28 Mckay Robert Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
US20030036516A1 (en) * 1997-09-10 2003-02-20 Sudhir Agrawal Method for using oligonucleotides having modified cpg dinucleotides
US6306831B1 (en) 1997-09-12 2001-10-23 Qik Technologies, Inc. Transplacental delivery of oligonucleotides
EP1469009A2 (de) * 1998-05-21 2004-10-20 Isis Parmaceuticals, Inc. Zusammensetzungen und Verfahren für nicht-parenterale Verabreichung von Oligonukleotiden
EP1080226A4 (de) * 1998-05-21 2004-04-21 Isis Pharmaceuticals Inc Zusammensetzungen und methoden zur topischen verabreichung von oligonukleotiden
EP1733735B1 (de) 1998-05-22 2017-03-22 Ottawa Hospital Research Institute Verfahren und Produkte zur Induktion von mukosaler Immunität
US6277967B1 (en) 1998-07-14 2001-08-21 Isis Pharmaceuticals, Inc. Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
US6867294B1 (en) * 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6242589B1 (en) 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
TR200102328T2 (tr) * 1999-02-12 2002-01-21 Sankyo Company Limited Yeni nükleosid ve oligonükleotid analogları
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
JP4151751B2 (ja) * 1999-07-22 2008-09-17 第一三共株式会社 新規ビシクロヌクレオシド類縁体
US20010011126A1 (en) * 1999-09-10 2001-08-02 Bock Elisabeth Marianne Neurogenic compositions and methods
US20050043262A1 (en) * 2000-03-29 2005-02-24 Weiss Robert H. Novel specific inhibitor of the cyclin kinase inhibitor p21Waf1/Cip1 and methods of using the inhibitor
AU2001261536A1 (en) * 2000-05-10 2001-11-20 Bristol-Myers Squibb Company Modified inosine 5'-monophosphate dehydrogenase polypeptides and uses thereof
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
KR100917101B1 (ko) * 2000-08-04 2009-09-15 도요 보세키 가부시키가이샤 플렉시블 금속적층체 및 그 제조방법
US7138259B2 (en) * 2000-09-12 2006-11-21 University Of Washington PDEs and uses thereof
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20050013853A1 (en) * 2000-11-29 2005-01-20 Irit Gil-Ad Anti-proliferative drugs
US20030096770A1 (en) * 2001-07-11 2003-05-22 Krotz Achim H. Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants
SI1446162T1 (sl) * 2001-08-17 2009-04-30 Coley Pharm Gmbh Kombinacija zaporedja imunostimulatornih oligonukleotidov z izboljšano aktivnostjo
US6630454B2 (en) 2001-09-10 2003-10-07 Ramot At Tel-Aviv University Ltd. Method and pharmaceutical composition for the treatment of cancer
WO2003064441A2 (en) 2002-02-01 2003-08-07 Mcgill University Oligonucleotides comprising alternating segments and uses thereof
US20030191075A1 (en) * 2002-02-22 2003-10-09 Cook Phillip Dan Method of using modified oligonucleotides for hepatic delivery
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040009483A1 (en) * 2002-07-12 2004-01-15 Ilsley Diane D. Method of linear mRNA amplification using total RNA
JP2004077714A (ja) * 2002-08-15 2004-03-11 Fuji Xerox Co Ltd 光走査装置
AU2003279004B2 (en) * 2002-09-28 2009-10-08 Massachusetts Institute Of Technology Influenza therapeutic
AU2003300919A1 (en) * 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
US8084432B2 (en) 2003-02-13 2011-12-27 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of pouchitis
WO2004092407A1 (en) * 2003-04-17 2004-10-28 Genesis Group Inc. Pygopus in diagnosis and treatment of cancer
DK1624936T3 (da) * 2003-05-16 2010-03-15 Univ Laval CNS-chloridmodulering og anvendelser deraf
US7960355B2 (en) * 2003-05-23 2011-06-14 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of the expression of B7 protein
US7897582B2 (en) * 2003-05-23 2011-03-01 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
WO2005013905A2 (en) * 2003-08-07 2005-02-17 Avi Biopharma, Inc. SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION
CA2540949A1 (en) * 2003-10-30 2005-05-12 Coley Pharmaceutical Gmbh C-class oligonucleotide analogs with enhanced immunostimulatory potency
US20080039528A1 (en) * 2004-03-17 2008-02-14 Kansas State University Research Foundation Zinc finger ejectors and methods of use thereof
US7718382B2 (en) * 2004-05-14 2010-05-18 Universite Laval Method for identifying compounds for treatment of pain
CA2567877A1 (en) * 2004-06-09 2005-12-22 Mcgill University Polynucleotides encoding acetylcholine-gated chloride channel subunits of caenorhabditis elegans
US8129352B2 (en) 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
US8357664B2 (en) * 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
US7524829B2 (en) * 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
WO2006113743A2 (en) * 2005-04-18 2006-10-26 Massachusetts Institute Of Technology Compositions and methods for rna interference with sialidase expression and uses thereof
CA2621964A1 (en) * 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
WO2007030691A2 (en) * 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
US8785407B2 (en) * 2006-05-10 2014-07-22 Sarepta Therapeutics, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
EP2057284A4 (de) * 2006-08-04 2011-06-29 Isis Pharmaceuticals Inc Zusammensetzungen und verfahren zur modulation von jnk-proteinen
PL2056845T3 (pl) 2006-08-08 2018-01-31 Univ Bonn Rheinische Friedrich Wilhelms Struktura i zastosowanie oligonukleotydów z 5'-fosforanem
EP2297323A1 (de) 2008-05-21 2011-03-23 Hartmann, Gunther 5 -triphosphat-oligonukleotid mit stumpfem ende und verwendugen davon
US20120128673A1 (en) 2009-05-20 2012-05-24 Schering Corporation Modulation of pilr receptors to treat microbial infections
TWI495473B (zh) 2009-11-13 2015-08-11 Sarepta Therapeutics Inc 反義抗病毒化合物及治療流感病毒感染的方法
US8691227B2 (en) 2009-12-17 2014-04-08 Merck Sharp & Dohme Corp. Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
US8198429B2 (en) 2010-08-09 2012-06-12 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
EP2508530A1 (de) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags
DK3505528T3 (da) 2011-04-21 2021-02-08 Ionis Pharmaceuticals Inc Modulation af hepatitis-b-virus (hbv)-ekspression
EP2712870A1 (de) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Neuartige RIG-I-Liganden und Herstellungsverfahren dafür
WO2014127479A1 (en) 2013-02-21 2014-08-28 Rsem, Limited Partnership Inhibition of sema3a in the prevention and treatment of ocular hyperpermeability
JP6794258B2 (ja) 2013-09-30 2020-12-02 ジェロン・コーポレーションＧｅｒｏｎ Ｃｏｒｐｏｒａｔｉｏｎ オリゴヌクレオチドについてのホスホロジアミデート骨格結合
KR20240125991A (ko) 2014-09-05 2024-08-20 알에스이엠, 리미티드 파트너쉽 염증을 치료 및 예방하기 위한 조성물 및 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4511713A (en) * 1980-11-12 1985-04-16 The Johns Hopkins University Process for selectively controlling unwanted expression or function of foreign nucleic acids in animal or mammalian cells
US4469863A (en) * 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
EP0092574B1 (de) * 1981-10-23 1992-04-29 Molecular Biosystems, Inc. Oligonukleotides heilmittel und dessen herstellungsverfahren
US4587044A (en) * 1983-09-01 1986-05-06 The Johns Hopkins University Linkage of proteins to nucleic acids
NZ209840A (en) * 1983-10-17 1988-11-29 Kaji Akira A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action
FR2568254B1 (fr) * 1984-07-25 1988-04-29 Centre Nat Rech Scient Application d'oligonucleotides lies a un agent intercalant, notamment a titre de medicament
WO1986005516A1 (en) * 1985-03-21 1986-09-25 Duke University Parasite-derived resistance
IL79391A (en) * 1985-08-14 1994-06-24 Hughes Aircraft Co Non-spherical patch with a stepped key and a display system that uses it
EP0252940A4 (de) * 1985-12-05 1989-07-27 Hutchinson Fred Cancer Res Antisense-rna zur behandlung von retroviralen krankheiten.
DE3782218T2 (de) * 1986-07-08 1993-05-06 Solidiwaste Technology L P Chemisches reagens und verfahren zur beseitigung von abfaellen.
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5110802A (en) * 1987-07-14 1992-05-05 City Of Hope Oligonucleotide phosphonates and method of inhibiting a human immunodeficiency virus in vitro utilizing said oligonucleotide phosphonates
US5004810A (en) * 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers

Also Published As

Publication number Publication date
CA2081777A1 (en) 1991-10-31
WO1991016902A1 (en) 1991-11-14
US5194428A (en) 1993-03-16
DE69129694D1 (de) 1998-08-06
EP0527906B1 (de) 1998-07-01
JPH05506997A (ja) 1993-10-14
EP0527906A1 (de) 1993-02-24

Similar Documents

Publication Publication Date Title
DE69129694D1 (de) Hemmung der replikation des influenza-virus durch oligonukleotide
DE68925278D1 (de) Hemmung von htlv-iii durch exogene oligonukleotide
ATE154029T1 (de) 7-deazapurin modifizierte oligonukleotide
BR0112540A (pt) Peptìdios como inibidores da ns-3-serina protease do vìrus da hepatite c
BR0010555A (pt) Inibidores de neuraminidases
WO1999054326A8 (de) Dihydropyrimidine
BRPI0411582A (pt) substáncias terapêuticas contendo boro hidroliticamente resistentes e método de uso
BRPI0408896A (pt) promotores de planta para uso no desenvolvimento precoce de sementes
MXPA05008368A (es) 1,2,4-triazinas inhibidoras del virus de inmunodeficiencia humana.
DE60018119D1 (de) Verfahren zur herstellung von polymorphen des clarithromycins
DE69626393D1 (de) Spezifische oligonukleotide für hepatitis b virus
DK0989973T3 (da) Chalconer med antiproliferativ aktivitet
FI922593A0 (fi) Inhibition av papillomavirus med çantisenseç-oligonukleotider.
ATE376445T1 (de) Synergistische hemmung von viralreplikation durch langkettigen kohlenwasserstoffe und nucleosid- analoge
JP2004091338A5 (de)
DK0644196T3 (da) TTTr som beskyttelsesgruppe i nucleotidsyntesen
UY26494A1 (es) " estabilización de vino"
DK1404844T3 (da) Fremgangsmåde til fremstilling af 2,4-dideoxyhexoser og 2,4,6-trideoxyhyxoser
BR9815081A (pt) Compostos tricìclicos, um processo para a sua preparação e composições farmacêuticas contendo-os
BR9909700A (pt) Oligonucleotìdeos anti-sentidos para a inibição de expressão de subunidade alfav de integrina
BR9914592A (pt) Processos de supressão de floração em plantas trangênicas
ATE265418T1 (de) Neue substituierte 3-phenoxy- und 3- phenylalkyloxy-2-phenyl-propylamine
Wallace et al. Global mitochondrial DNA variation and the origin of Native Americans
KR950023404A (ko) 5-히드록시메틸-2-푸르푸랄을 함유하는 비(b)형 간염 치료제
ATE250049T1 (de) Verfahren um 2-brom-5-(2-brom-2-nitrovinyl)-furan zu erhalten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties